{"id":"NCT02540993","sponsor":"Bayer","briefTitle":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-17","primaryCompletion":"2020-04-14","completion":"2020-04-14","firstPosted":"2015-09-04","resultsPosted":"2021-07-19","lastUpdate":"2023-07-24"},"enrollment":5734,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Finerenone (BAY94-8862)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Finerenone (BAY94-8862)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.","primaryOutcome":{"measure":"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death","timeFrame":"From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months","effectByArm":[{"arm":"Finerenone","deltaMin":504,"sd":null},{"arm":"Placebo","deltaMin":600,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0014"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":978,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Philippines","Poland","Portugal","Puerto Rico","Romania","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["31655812","33264825","33198491","40526444","40315020","39380152","38508632","38048573","38046911","37872654","37745646","36927680","36864892","36639130","36328655","36287567","36252131","36251465","35061867","35005312","34850173","34015478","33358451","33280027","33107592"],"seeAlso":["https://clinicaltrials.bayer.com/","http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":902,"n":2827},"commonTop":["Hyperkalaemia","Nasopharyngitis","Oedema peripheral","Hypertension","Anaemia"]}}